Aralez Bio
Americas
Berkeley
,
United States
Startup
FOUNDED
2019
HEADCOUNT
21-100
FUNDING
Series A
Keywords:
enzymes, biocatalysis, amino_acids, therapeutics
BUSINESS
Develops proprietary enzymatic synthesis of noncanonical amino acids (ncAAs), single-step, enantiopure production. ncAAs are building blocks in >10% of all pharmaceuticals, including GLP-1 drugs like Ozempic and Mounjaro. Moved to ton-scale production facility in Berkeley in 2025. Partnership with Resilience for cGMP manufacturing of pharmaceutical amino acid ingredients. Revenue-generating partnerships with top-five global pharma companies.
BIOTECH INVOLVEMENT
Core; develops proprietary enzymatic synthesis of non-canonical amino acids (ncAAs) as single-step enantiopure routes to building blocks used in >10% of pharmaceuticals (including GLP-1 drugs such as Ozempic and Mounjaro).
TECHNOLOGY PLATFORM
engineered enzyme platform; biocatalysis
PRIMARY PRODUCTS
noncanonical amino acids (e.g., Fmoc-7-Methyl-L-Tryptophan)